Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580545 | 0.86 | POLB (0.47) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL1578863 | 0.85 | MEN1 (0.45) | ALDH1A1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL27834976 | 0.83 | MEN1 (0.41) | ALDH1A1MEN1KMT2ALMNATP53 | |
| SCHEMBL1580417 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL29089138 | 0.81 | POLB (0.56) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL31167811 | 0.81 | MEN1 (0.52) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL14598714 | 0.81 | OPRK1 (0.48) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL10306721 | 0.80 | MAPT (0.47) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL1522008 | 0.80 | MEN1 (0.50) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL14598663 | 0.80 | MEN1 (0.53) | ALDH1A1MEN1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| EP-2310381-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009150230-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150230-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | ALDH1A1 93/4885MEN1 1570/4885KMT2A 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.